<DOC>
	<DOCNO>NCT00257075</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety risperidone ( antipsychotic medication ) versus placebo 3 week treatment mania patient Bipolar I Disorder suffer manic episode .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Versus Placebo Treatment Manic Episodes Associated With Bipolar I Disorder</brief_title>
	<detailed_description>Antipsychotic agent , long time , use alleviate severe behavioral problem associate manic episode . Risperidone , widely use treatment schizophrenia , show effective treatment manic mixed episode associate bipolar disorder . This randomized , double-blind , placebo-controlled study evaluate effectiveness safety risperidone compare placebo treatment patient bipolar disorder experience manic episode . Patients receive study medication ( risperidone placebo tablet ) take orally day gradually increase dos first week achieve optimal effectiveness , minimize intolerance drug . By Day 4 , dose risperidone range 1 6 mg/day , treatment risperidone placebo tablet continue 3 week . The primary measure effectiveness change Young Mania Rating Scale ( YMRS ) total score baseline end treatment . Additional assessment effectiveness include Clinical Global Impression-Severity Illness ( CGI-S ) scale ; Global Assessment Scale ( GAS ) , assess patient 's level functioning ; Positive Negative Syndrome Scale ( PANSS ) , scale measure psychotic symptom . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( temperature , pulse , blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) specify interval ; clinical laboratory test ( hematology , biochemistry , urinalysis ) start end study . The study hypothesis daily treatment risperidone effective placebo , measure Young Mania Rating Scale score , treatment manic phase Bipolar I Disorder . Risperidone tablets,1 mg ( placebo tablet ) take orally daily evening ; dose 3 mg Day 1 ; dose range 2 - 4 mg Day 2 ; dose range 1 - 5 mg Day 3 ; dose range 1 - 6 mg Days 4 - 21 . Doses may increase decreased investigator 's discretion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients diagnosis Bipolar I Disorder , Most Recent Episode Manic , criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) voluntarily hospitalize study initiation current manic episode history least one document manic mixed episode require treatment prior study initiation total score &gt; =20 Young Mania Rating Scale ( YMRS ) total score &lt; =20 Montgomery Asberg Depression Rating Scale ( MADRS ) start study Patients meet DSMIV criterion Schizoaffective Disorder rapid cycling borderline antisocial personality disorder history substance dependence ( exclude nicotine caffeine ) within 3 month prior study initiation seizure disorder female pregnant nursing , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>manic episode</keyword>
</DOC>